AU2003288231A8 - Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease - Google Patents

Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease

Info

Publication number
AU2003288231A8
AU2003288231A8 AU2003288231A AU2003288231A AU2003288231A8 AU 2003288231 A8 AU2003288231 A8 AU 2003288231A8 AU 2003288231 A AU2003288231 A AU 2003288231A AU 2003288231 A AU2003288231 A AU 2003288231A AU 2003288231 A8 AU2003288231 A8 AU 2003288231A8
Authority
AU
Australia
Prior art keywords
cyp46
hydroxylase
alzheimer
cholesterol
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003288231A
Other versions
AU2003288231A1 (en
Inventor
Yan-Hong Liu
Stefan Golz
Gerhard Konig
Martin Guldenagel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer Healthcare AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare AG filed Critical Bayer Healthcare AG
Publication of AU2003288231A1 publication Critical patent/AU2003288231A1/en
Publication of AU2003288231A8 publication Critical patent/AU2003288231A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/60—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving cholesterol
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
AU2003288231A 2002-12-13 2003-12-05 Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease Abandoned AU2003288231A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02027692.9 2002-12-13
EP02027692 2002-12-13
PCT/EP2003/013760 WO2004055201A2 (en) 2002-12-13 2003-12-05 Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease

Publications (2)

Publication Number Publication Date
AU2003288231A1 AU2003288231A1 (en) 2004-07-09
AU2003288231A8 true AU2003288231A8 (en) 2004-07-09

Family

ID=32524000

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003288231A Abandoned AU2003288231A1 (en) 2002-12-13 2003-12-05 Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease

Country Status (2)

Country Link
AU (1) AU2003288231A1 (en)
WO (1) WO2004055201A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8198257B2 (en) 2007-09-12 2012-06-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) CYP46A1 gene for the treatment of alzheimer's disease
EP2627359B1 (en) 2010-10-15 2015-12-30 INSERM - Institut National de la Santé et de la Recherche Médicale Expression vector for cholesterol 24-hydrolase in therapy of huntington's disease
CN107936076B (en) 2011-09-08 2021-10-15 萨奇治疗股份有限公司 Neuroactive steroids, compositions, and uses thereof
MX360706B (en) 2011-10-07 2018-11-14 Takeda Pharmaceuticals Co 1 - arylcarbonyl - 4 - oxy - piperidine compounds useful for the treatment of neurodegenerative diseases.
BR112015022934A8 (en) * 2013-03-13 2019-11-26 Sage Therapeutics Inc neuroactive steroids, compositions and uses of these
JP6255082B2 (en) 2013-03-13 2017-12-27 セージ セラピューティクス， インコーポレイテッド Nerve stimulating steroids and methods of use thereof
EP3157528B1 (en) 2014-06-18 2023-09-13 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
JP2018519351A (en) 2015-07-06 2018-07-19 セージ セラピューティクス， インコーポレイテッド Oxysterols and methods of their use
AU2016289965B2 (en) 2015-07-06 2021-09-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
KR20180026742A (en) 2015-07-06 2018-03-13 세이지 테라퓨틱스, 인크. Oxysterol and its use
BR112018070123A2 (en) 2016-04-01 2019-02-05 Sage Therapeutics Inc oxiesterós and methods of use thereof
WO2017193046A1 (en) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
LT3481846T (en) 2016-07-07 2021-08-25 Sage Therapeutics, Inc. 11-substituted 24-hydroxysterols for use in the treatment of nmda related conditions
MA46351A (en) 2016-09-30 2021-06-02 Sage Therapeutics Inc C7 SUBSTITUTED OXYSTEROLS AND PROCESSES AS NMDA MODULATORS
KR20230051723A (en) 2016-10-18 2023-04-18 세이지 테라퓨틱스, 인크. Oxysterols and methods of use thereof
CN115181153A (en) 2016-10-18 2022-10-14 萨奇治疗股份有限公司 Oxysterol and methods of use thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003046579A2 (en) * 2001-11-09 2003-06-05 University Of Zürich Cyp46 genotype determination for risk and treatment evaluation of alzheimer's disease

Also Published As

Publication number Publication date
AU2003288231A1 (en) 2004-07-09
WO2004055201A3 (en) 2004-08-19
WO2004055201A2 (en) 2004-07-01

Similar Documents

Publication Publication Date Title
AU2003229937A1 (en) Alkynyl-substituted spirocyclic sulfamides for the treatment of alzheimer's disease
SI2527315T1 (en) Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as Alzheimer's disease, type 2 diabetes and Parkinson's disease
EP1940373B8 (en) 1-fluoro-1-deoxy-scyllo-inositol for the treatment of alzheimer's disease
HUS1500043I1 (en) Methods for treatment of parkinson's disease
IL160884A0 (en) Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
AU2003288231A8 (en) Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease
IL209842A0 (en) Compounds for the treatment of metabolic disorders
AU2003206413A1 (en) Substituted amino carboxamides for the treatment of alzheimer's disease
IL159344A0 (en) Quinuclidines-substituted-multicyclic-heteroaryls for the treatment of disease
AU2003217275A1 (en) Azabicyclic compounds for the treatment of disease
AU2002315131A1 (en) Aminediols as agents for the treatment of alzheimer's disease
AU2002312897A1 (en) Drugs for the treatment of the alzheimer disease
AU2003303141A1 (en) Hydroxypropyl amides for the treatment of alzheimer's disease
AU2003254146A1 (en) Methods for the treatment of parkinson's disease
AU2003273310A1 (en) Substituted aminoethers for the treatment of alzheimer's disease
AU2003284898A1 (en) Combinative nicotinic/d1 agonism therapy for the treatment of alzheimer's disease
EP1181550A4 (en) Methods for the identification of compounds for the treatment of alzheimer's disease
AU2003299101A1 (en) Compounds for the treatment of alzheimer's disease
EP1546120A4 (en) Pharmaceutical compositions for treatment of parkinson's disease
AU2003216696A8 (en) Methods for the selection of compounds useful for the treatment of huntington's disease
AU2003260745A1 (en) Sulphonylamino derivatives for the treatment of alzheimer's disease
GB0222282D0 (en) Therapeutic device for the treatment of symptons caused by diseases
AU2002316622A1 (en) Aminediols for the treatment of alzheimer's disease
AU2002320537A1 (en) Diaminediols for the treatment of alzheimer's disease
AU2002351935A1 (en) Compounds for the diagnosis/prevention/treatment of alzheimer's disease

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase